Breakdown of 108,000 weight management subscribers (compounded vs. branded GLP-1), economics of branded GLP-1s, and if LifeMD receives fulfillment fees from Lilly/Novo.

Justin Schreiber clarified that for new patients, almost 95% are on branded therapy, making the compounding business very small and insignificant to future earnings. He emphasized positive unit economics for branded GLP-1s over 2-3 years, with potential for cross-care offerings and partnerships to drive patient acquisition. Atul Kavthekar added that the shift to multi-month subscribers significantly improves unit economics and cash payback. LifeMD currently receives no economics from Lilly/Novo, only integration. “for new patients, almost 95% of new patients are going on a branded therapy. Very few patients are getting a prescription for a personalized compound.”

Given 2026 is a build year, what is the potential for 2027 EBITDA margin growth compared to the 10% exit rate, and which of the new channels (Zyosted, Medicare, employer, pharmacy) will show visible impact first?

Atul Kavthekar stated optimism for the core business and new product introductions shaping 2027 guidance. Zyosted is in early stages and will be in growth/investment mode for a few quarters before contributing to EBITDA. He implied that the core business improvements and new product pipeline will likely show visible impact first. “there's going to be a real visible showing from the core business that we're in. One of the things that's not even factored into our guidance in the year is the introduction of a number of new products that are in the pipeline.”

Where does LifeMD stand with deep customer relationships across multiple health areas and pharmacy today, versus where it could be in a couple of years?

Justin Schreiber explained that "deeper relationships" mean patients using the platform for many aspects of their healthcare. He cited women's health as an example, where patients start with hormone therapy and then use sexual wellness, weight loss, and in-home labs. He highlighted plans for a bone health program and leveraging AI with integrated medical and lab data to provide longitudinal, personalized care. “I mean, when we say deeper relationships, right, we just mean patients being able to use our platform for many different aspects of their healthcare.”

LFMD

LifeMD (LFMD) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 5, 2026

Source: earnings call transcript

Executive summary

LifeMD, Inc. Q2 FY26 — Strategic Shift Towards Quality Revenue and Diversified Growth

LifeMD's Q2 FY26 results reflect a strategic pivot towards quality revenue and diversified patient acquisition channels, moving beyond a reliance on paid media. While this transition led to a near-term adjusted EBITDA miss and a revised full-year outlook, the company reported strong underlying improvements in recurring revenue mix, gross margin, and operating costs. Management is focused on building longer-term patient relationships through branded therapies, pharmacy expansion, and strategic partnerships, aiming for a return to adjusted EBITDA profitability in Q3.

Highlights

Recurring rebill revenue represented approximately 84% of total revenue.
Gross margin expanded to approximately 89%, an improvement of approximately 60 basis points sequentially.
Advertising and marketing expense declined by approximately $1.8 million sequentially.
Other general and administrative expenses declined approximately $1.5 million sequentially.
Women's health patient base grew 134% quarter over quarter.

Concerns

Adjusted EBITDA was a loss of approximately $3.5 million, missing internal targets.
Revenue was $47.3 million, within guidance but down approximately 6% sequentially and 4% year-over-year.
Elevated customer acquisition costs (CAC) early in the quarter due to competitive market for GLP-1s.
Lower upfront revenue associated with the new $39 introductory GLP-1 pricing.
Full-year 2026 adjusted EBITDA outlook revised to negative $6 million to break even, down from prior expectations.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Revenue	$205.5 million to $212.5 million high materiality	FY26	High
Full-year 2026 Adjusted EBITDA	negative $6 million to break even high materiality	FY26	High
Q3 FY26 Revenue	$48 million to $51 million medium materiality	Q3 · FY26	High
Q3 FY26 Adjusted EBITDA	negative $1 million to positive $2 million medium materiality	Q3 · FY26	High
Q4 FY26 Revenue	$60 million to $64 million medium materiality	Q4 · FY26	High
Q4 FY26 Adjusted EBITDA	$3 million to $6 million medium materiality	Q4 · FY26	High
Q4 FY26 Annualized Revenue Run Rate	approximately $250 million high materiality	Q4 · FY26	High
Q4 FY26 Annualized Adjusted EBITDA Run Rate	approximately $22 million high materiality	Q4 · FY26	High
Zyosted Launch Investment	$2 million to $3 million medium materiality	FY26	High
Zyosted EBITDA Accretion	accretive to LifeMD's EBITDA medium materiality	mid-2027 · FY27	Medium
Women's Health Patient Base Growth	another 300% to 400% medium materiality	by the end of the year · FY26	High
Compounded Products Launch	more than 30 compounded products low materiality	between now and year-end · FY26	High
Women's Health Quarterly Revenue Run Rate	between $3 million and $5 million medium materiality	Q4 · FY26	Medium

Product announcements

Product	Type	Timeline	Details
Compounded Products	launch	between now and year-end (FY26)

Deals & partnerships

Halazime's wholly-owned subsidiary, Anteros Pharma Exclusive telehealth co-marketing collaboration for Zyosted, an FDA-approved, once-weekly, subcutaneous testosterone autoinjector.

Initial self-pay program launched in July across 37 states at $249 per month, with affiliated pharmacies as primary dispensing. Expect insurance access to become important. Direct costs split between the two companies.

Risks & headwinds

Elevated customer acquisition costs Early Q2 FY26

Elevated early in Q2, particularly for branded GLP-1 care; contributed to adjusted EBITDA shortfall.

Mitigation:Restructured customer acquisition model, shifting mix away from sole reliance on paid media to alternative channels (pharmaceutical manufacturers, employers, insurers, Medicare, referrals). CAC for weight management down 50% since mid-June.

Competitive pricing in weight management Early Q2 FY26

Affected conversion and made LifeMD's offering less competitive at the top of the funnel.

Mitigation:LifeMD responded by lowering introductory price of branded GLP-1 program to $39, which reduced upfront cash collection but materially improved program attraction and increased multi-month package selection from 25% to 85%.

Near-term profitability pressure from strategic changes Q2 FY26 and H2 FY26

Adjusted EBITDA loss of approximately $3.5 million; full-year adjusted EBITDA outlook revised to negative $6 million to break even.

Mitigation:Expense actions (advertising/marketing down $1.8M sequentially, G&A down $1.5M sequentially) expected to become more visible in H2. Focus on executing against outlook for return to adjusted EBITDA profitability in Q3 and substantial sequential improvement in Q4.

Compounding business shrinking faster than expected Throughout FY26

Very few new patients getting prescriptions for personalized compounds (other 5% of new patients, 95% on branded therapy); patients previously on compounds switched to branded therapies faster.

Mitigation:Company views compounding as insignificant to future earnings and is focusing on branded therapies and pharmacy expansion.

Startup investment required for Zyosted collaboration 2026 and early 2027

Anticipated $2 million to $3 million investment in 2026.

Mitigation:Investment is contemplated in the revised outlook; initial cohorts expected to become accretive to EBITDA in mid-2027.

What to watch in Q3 FY26

Adjusted EBITDA Profitability

Q3 FY26

Current Negative $3.5 million (Q2 FY26)

Target Negative $1 million to positive $2 million (Q3 FY26)

Why it matters

Management expects a return to adjusted EBITDA profitability in Q3, which is critical for validating the strategic shift and expense management efforts.

We expect a return to adjusted EBITDA profitability in the third quarter and deliver substantial sequential improvement in the fourth quarter.

Find out whether LFMD delivers this. Inve re-checks your case every morning.

Q&A highlights

What is the potential revenue opportunity for peptides if FDA permits compounding, and what is LifeMD's approach?

Justin Schreiber stated that while there's no specific revenue number, there would be considerable demand from current patients across weight loss, hormones, and sexual health, as well as outside the platform. LifeMD plans a conservative approach, ensuring safety and proper prescription, and is working on sterile compounding capabilities or vendor partnerships.

“if FDA follows through as they're expected to and permits some of them to be made in compounding pharmacies... it would be a pretty significant market opportunity for LifeMD.”

asked by David Larson · answered by Justin Schreiber

2 min read 6 chapters

Detailed narrative

Strategic Shift in Patient Acquisition

LifeMD is deliberately moving away from a sole reliance on paid media due to volatile auction pricing and shallow patient relationships. The company is diversifying demand channels to include pharmaceutical manufacturers (e.g., Zyosted collaboration), employers, insurers, Medicare, and patient referrals, aiming for more diversified, less volatile, and more valuable growth. Early results show acquisition costs for weight management down 50% from peak in June.

Evolution of Weight Management Business

The company is building its weight management business around branded, FDA-approved GLP-1 therapies and longitudinal clinical care, including insurance access and manufacturer relationships. A recent pricing change to $39 for the introductory GLP-1 program, while impacting upfront cash, has significantly increased the selection of multi-month packages from 25% to 85%, leading to higher retention and lifetime value.

Growth in Women's Health

The women's health program, designed for longitudinal, evidence-based care, saw its patient base grow 134% quarter over quarter and is expected to grow another 300-400% by year-end. This program integrates hormone therapy, sexual wellness, weight loss, and in-home labs, with plans for a bone health program, demonstrating the company's focus on deep patient relationships and cross-care offerings.

Pharmacy Expansion and Capabilities

LifeMD's 50-State Pharmacy is becoming a strategic asset, contributing to gross margin expansion with operations carrying approximately 90% gross margins. The pharmacy is scaling across branded direct-to-patient fulfillment (e.g., Zyosted), generic medications, and personalized compounding therapies. The company plans to launch over 30 compounded products by year-end across various health categories.

Investment in Affiliated Medical Group and Technology

The company is strengthening its affiliated medical group by hiring 47 new providers and cross-training them across men's and women's health offerings to support anticipated demand. Technology investments, particularly in AI, are embedded across the platform to improve intake, clinical decision support, patient messaging, and back-office workflows, aiming to reduce cost per patient and cost per consult.

Insurance and Strategic Partnerships

LifeMD's benefits infrastructure now reaches approximately 175 million covered lives, with insurance penetration at about 10% for new primary care patients. The company is also advancing national strategic and employer partnerships to increase brand awareness and patient volume at attractive economics, reducing dependence on media-based acquisition.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.